Showing results (181-190 of 219) with videos related to

Sort By:
Pageof 22
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2026
Phase I Study of Rogocekib in Patients with Advanced, Relapsed, or Refractory Malignant Solid TumorsJun Sato, Yuki Katsuya, Takafumi Koyama, et al.
Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology|January 17, 2015
Effects of low frequency filtering on distal compound muscle action potential duration for diagnosis of CIDP: A Japanese-European multicenter prospective studySatsuki Mitsuma, Peter Van den Bergh, Yusuf A Rajabally, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|January 16, 2024
Diagnostic utility of Gold Coast criteria for amyotrophic lateral sclerosis in AsiaRyo Otani, Kazumoto Shibuya, Toshio Shimizu, et al.
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|September 2, 2023
The necessity to improve disaster preparedness among patients with amyotrophic lateral sclerosis and their familiesTakehisa Hirayama, Mari Shibukawa, Harumi Morioka, et al.
Cancer Research Communications|March 27, 2023
Safety, Tolerability, and Pharmacokinetics of TAK-931, a Cell Division Cycle 7 Inhibitor, in Patients with Advanced Solid Tumors: A Phase I First-in-Human StudyYasutoshi Kuboki, Toshio Shimizu, Kan Yonemori, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 10, 2014
Phase I first-in-human study of CUDC-101, a multitargeted inhibitor of HDACs, EGFR, and HER2 in patients with advanced solid tumorsToshio Shimizu, Patricia M LoRusso, Kyri P Papadopoulos, et al.
Frontiers in Oncology|February 17, 2025
Corrigendum: First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP: TGF-ß1 complex, as monotherapy and in combination with the anti-PD-1 antibody budigalimab in patients with advanced solid tumorsToshio Shimizu, John Powderly, Albiruni Abdul Razak, et al.
Frontiers in Oncology|November 13, 2024
First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP:TGF-ß1 complex, as monotherapy and in combination with the anti-PD-1 antibody budigalimab in patients with advanced solid tumorsToshio Shimizu, John Powderly, Albiruni Abdul Razak, et al.
Cancer Science|September 9, 2022
First-in-human study of ONO-4578, an antagonist of prostaglandin E<sub>2</sub> receptor 4, alone and with nivolumab in solid tumorsSatoru Iwasa, Takafumi Koyama, Makoto Nishino, et al.
Cancer Treatment Reviews|March 19, 2024
Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecanRebecca S Heist, Jacob Sands, Aditya Bardia, et al.
Pageof 22